分娩后新发持续性阿片类药物使用
基于人群的队列研究纳入2013年9月1日至2021年9月30日出院后7天内启动阿片类药物治疗的118,694例分娩,其中剖宫产99,399例(83.7%)、阴道分娩19,295例(16.3%);1,282例(10.8/1000次分娩)在随后一年符合新发持续性阿片类药物使用定义,阴道分娩后发生率(16.0/1000)高于剖宫产(9.8/1000);初始处方每增加30毫克吗啡当量及剖宫产后合用苯二氮䓬类药物与风险升高相关。
要点
- 分娩后启动阿片类药物者中约1%在随后一年出现持续性使用。
- 阴道分娩后新发持续性阿片使用率(16.0/1000)高于剖宫产(9.8/1000)。
- 初始阿片处方每增加30毫克吗啡当量,剖宫产aOR 1.06、阴道分娩aOR 1.05。
核心结论
- 在分娩后填写阿片类药物处方的人群中,约1%在随后一年表现出持续性阿片类药物使用的证据。
- 初始处方开具大量阿片类药物以及同时开具苯二氮䓬类药物可能是预防分娩后新发持续性阿片类药物使用的重要可干预危险因素。
研究设计与样本
- 基于人群的队列研究,纳入2013年9月1日至2021年9月30日出院后7天内启动阿片类药物治疗的分娩个体。
- 共识别118,694例启动阿片类药物的独特分娩,包括剖宫产99,399例(83.7%)和阴道分娩19,295例(16.3%)。
- 主要结局为新发持续性阿片类药物使用,定义为首次产后处方后90天内有一个或多个阿片类药物处方,且此后91至365天期间有一个或多个后续阿片类药物处方。
- 采用多变量逻辑回归评估与分娩后新发持续性阿片类药物使用相关的患者、妊娠和处方因素。
主要发现
- 1,282例(10.8/1000次分娩)在随后一年符合新发持续性阿片类药物使用定义。
- 新发持续性阿片类药物使用率在阴道分娩后(16.0/1000)明显高于剖宫产(9.8/1000)。
- 初始阿片处方每增加30毫克吗啡当量,剖宫产后新发持续性使用风险升高(aOR 1.06,95% CI 1.04-1.08),阴道分娩后亦升高(aOR 1.05,95% CI 1.02-1.08)。
- 剖宫产后同时开具苯二氮䓬类药物与新发持续性阿片类药物使用风险显著升高相关(aOR 2.69,95% CI 1.60-4.52)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine factors associated with new persistent opioid use after childbirth. METHODS: We conducted a population-based cohort study of individuals who initiated opioid therapy within 7 days of discharge from hospital after delivery between September 1, 2013, and September 30, 2021. The primary outcome was new persistent opioid use , which was defined as one or more prescriptions for an opioid within 90 days of the first postpartum prescription and one or more subsequent opioid prescriptions in the 91-365 days afterward. We used multivariable logistic regression to assess patient-, pregnancy-, and prescription-related factors associated with new persistent opioid use after delivery. RESULTS: We identified 118,694 unique deliveries after which opioids were initiated, including 99,399 cesarean (83.7%) and 19,295 vaginal (16.3%) deliveries. Among mothers who initiated an opioid after delivery, 1,282 (10.8/1,000 deliveries) met our definition of new persistent opioid use in the subsequent year. Rates of new persistent opioid use were appreciably higher after vaginal (16.0/1,000) compared with cesarean (9.8/1,000) deliveries. Each additional 30 morphine milligram equivalents in the initial opioid prescription was associated with an increased risk of new persistent use after cesarean (adjusted odds ratio [aOR] 1.06, 95% CI 1.04-1.08) and vaginal (aOR 1.05, 95% CI 1.02-1.08) delivery. A concomitant benzodiazepine prescription after cesarean delivery was associated with a markedly increased risk of persistent opioid use (aOR 2.69, 95% CI 1.60-4.52). CONCLUSION: Among people who filled an opioid prescription after delivery, about 1% displayed evidence of persistent opioid use in the subsequent year. Initial prescriptions for large quantities of opioids and a concurrent benzodiazepine prescription may be important modifiable risk factors to prevent new persistent opioid use after delivery.
引用
- Zipursky JS, Everett K, Calzavara A, et al. New Persistent Opioid Use After Childbirth. Obstet Gynecol. 2023. PMID: 37917933. doi:10.1097/AOG.0000000000005432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。